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ABSTRAK.
Latar belakang. Multiple myeloma (MM) adalah keganasan yang membedakan karakter B-limfosit ditandai 
dengan akumulasi sel plasma klon dalam sumsum tulang (BM), adanya imunoglobulin monoklonal (Ig) dalam 
serum atau urine, dan lesi tulang osteolitik.1 Komplikasi penyakit ini terdiri dari infeksi bakteri berulang, 
anemia, lesi osteolitik dan penurunan fungsi ginjal.2-5 MM adalah penyebab 1% kematian dari kematian 
akibat kanker di negara-negara Barat. Insiden MM adalah 1% dari semua keganasan dan 10% dari keganasan 
hematologi di ras Kaukasia dan 20% di ras Afro Amerika.2
Tujuan. Tujuan dari penelitian ini adalah untuk mengetahui data deskriptif  karakteristik pasien dengan 
Multiple Meyloma di Rumah sakit dr. Kariadi Semarang.
Metode. Meskipun pembangunan di manajemen pasien, MM masih penyakit yang tak tersembuhkan, dengan 
tingkat ketahanan hidup 5 tahun lebih rendah dari 40%. Ada banyak perbedaan di myeloma dan manifestasi 
klinis. Beberapa pasien dapat bertahan di bulan sampai lebih dari 10 tahun.5,6,7 Kelangsungan hidup rata-rata 
adalah 33 bulan, jumlah ini sama dalam studi Asia.8,9
Hasil.Ada beberapa faktor prognostik dalam manajemen myeloma, seperti β2-mikroglobulin (β2m), albumin 
serum, serum kreatinin, persentase sel plasma di sumsum, tulang litik lesi, β2m anemia.10-13 merupakan 
faktor prognostik yang digunakan oleh Sistem Staging Internasional (ISS)11 untuk menentukan stadium dan 
prognosis di MM. β2m berkorelasi dengan faktor-faktor lain, seperti kreatinin serum, anemia, mekanisme 
kerusakan tulang pada pasien MM.11,13
Kesimpulan. MM di Indonesia belum diteliti secara komprehensif  sedangkan pengukuran β2m mahal dan 
tidak tersedia secara luas.
Kata kunci: Multiple Myeloma, Sumsum tulang, Prognosis Factors
ABSTRACT
Background. Multiple myeloma (MM) is a malignancy of  differentiated B-lymphocytes characterized by 
accumulation of  clonal plasma cells in the bone marrow (BM), the presence of  a monoclonal immunoglobulin 
(Ig) in the serum and/or urine, and osteolytic bone lesions.1 Complications of  this disease consist of  
recurrent bacterial infection, anemia, osteolytic lesion and decreased renal function.2-5   MM is the cause of  
death in 1% of  cancer death in Western countries. MM incidence is 1% of  all malignancies and 10% of  
hematologic malignancies in Caucasian race and 20% in the Afro American race.2
Aim. The aim of  the study is to know the descriptive data of  characteristic of  patients with MM at dr. 
Kariadi Hospital Semarang. 
Metode. Despite of  development in patient management, MM is still an incurable disease, with 5-year 
survival rates lower than 40%. There are many differences in myeloma and its clinical manifestations. Some 
patients can survive in the months until over than 10 years.5, 6, 7 The median survival was 33 months, this 
number is similar in Asian studies.8, 9 
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MATERIAL AND METHOD
This is a cross sectional study. The 
design and conduct of  the study complied 
with the principles of  good clinical practice, 
in accordance with the Declaration of  
Helsinki. The study was approved by local 
ethics committees and written informed 
consent was obtained from all patients before 
enrollment. The patients are older than 14 
years old, who are new and old patients 
diagnosed with MM that referred to dr. 
Kariadi Hospital Semarang.
Patients were evaluated for physical 
examination, laboratory measurement, and 
bone survey. Complete blood count was 
analyzed using ABX Micros 60®. Creatinine 
serum was measured from blood clot using 
Gas-chromatography-isotope dilution mass 
spectral method. Albumin serum was measured 
using Bromocresol green method. Beta-
microglobulin was analyzed using Enzyme-
linked immunosorbent assays (ELISA) 
method. Immunofi xation was analyzed using 
the Hellabio Immunofi xation Electrophoresis 
(IFE). 
Data Analysis
Data were analyzed using SPSS 12 
evaluation version. The data showed as 
descriptive method.
RESULTS 
Demographic Characteristic 
Between January and December 2010, 
25 patients with clinical diagnosis of  MM 
were included in this study. The demographic 
characteristics were shown in Table 1. Median 
age was 56 (SE ±1.8). The study population 
was mostly men (79%). Private employee, 
government employee, farmer, entrepreneur, and 
others were 13 patients (52%), 7 patients (28%), 2 
patients (8%), 2 patients (8%), and 1 patient (4%), 
respectively.  The main complaint was bone pain, 
this occurred in 15 patients (60%), followed by 
shortness of  breath in 4 patients (16%), swelling 
of  shoulder in 1 patient (4%), forehead tumor in 
1 patient (4%), petechiae in 1 patient (4%), fatigue 
in 1 patient (4%), weakness in 1 patient (4%), 
bone pain in 1 patient (4%), and bone fracture 
in 1 patient (4%).
Laboratory characterizations were shown 
in Table 2.  The majority of  patients have anemia 
with mean Hb level of  9.4 g/dL (SD±2.7). 
Leukocyte and Platelet counts were normal, 7.4 
g/dL (SD ±2.9) and 200.3 x 103 /mm3(SD±124) 
respectively. The mean creatinine level was 1.7 
mmol/L (SD±1.1). There was hypoalbuminemia 
with mean albumin level of  2.6 g/dL (SD±0.6), 
hyperglobulinemia with mean globulin level of  
6.9 g/dL (SD ± 1.8) and normal calcium level 
with a mean of  2.3 mmol/L (SD± 0.4). The 
mean β2m level was 9.6 g/dL (SD±8.9). 
Results. There are several prognostic factors in myeloma management, such as β2-Microglobulin (β2m), 
serum albumin, serum creatinine, plasma cell percentage in marrow, bone lytic lesion, anemia.10-13 β2m is a 
prognostic factor used by the International Staging System (ISS)11 to determine stadium and prognosis in 
MM. β2m correlates with other prognostic factors, such as serum creatinine, anemia, mechanism of  bone 
destruction in MM patients.11, 13 
Conclusion. MM in Indonesia has not been studied comprehensively and the β2m measurement is expensive 
and not widely available. 
Keywords:  Multiple Meyloma,  bone marrow,  prognostic factors
Suharti et al.
24 
(8%), 1 patient (4%), and 1 patient (4%), 
respectively.  Thirty six (36%) patients have not 
been classifi ed. The Bone survey examination 
showed that most of  the patients have bone 
lytic lesion, 21 patients (88%). 
Table 2. The Laboratory data of  patient 
with Multiple myeloma
Variable  Mean (± SD)
Hemoglobine, gr/dL
Leucocyte x 103/mm3
Platelet x103/mm3
Creatinine, mmol/L
Albumin, g/dL
Globulin, g/dL
Calcium, mmol/L
β2m,  mg/dL
9.4 ± 2.7
7.4 ± 2.9
200.3 ±124
1.7±1.1
2.6 ±0.6
6.9 ± 1.8
2.3 ± 0.4
9.6 ±8.9
Table 3. Patient clasifi cation with MM 
based on monoclonal protein
Immunoisotipe total (%)
IgG κ
IgA κ
IgA λs
Biclonal λ light cain  and IgG κ
Light-chain κ
Not classifi ed
11 (44)
2 (8)
1 (4)
1(4)
1 (4)
9 (36)
 
Table 4. Osteolytic Lesion of  patient 
with MM
Number of  osteolytic bone, % Total (%)
0 (no osteolytic)
1 
2 
3 
4 
5
6
7
4 (12)
1 (4)
12(48)
4 (16)
2 (8)
1 (4)
0
1 (4)
DISCUSSION
The median age of  this study population 
was 56 years. Median age in a study in Taiwan 
was 62 years.14  Median age in Royal Free 
Myeloma Clinic study was 67 years for 
Table 1. The demographic data of  25 
patients with MM
Characteristic All patient (N= 25)
Age at diagnosis, year * 56 (1.8)
Sex, Man/Woman (%)
Occupation (%)
   Farmer 
   Government  employee
   Private employee
   Entrepreneur
   Others
Main complaint (%)
   Shoulder swelling
   Tumor in forehead
   Ecchymosis
   Fatigue
   Weakness
   Bone pain
   Bone fracture
   Shortness of   breath
Complication (%)
   Fracture
   Recurrent infection
   Renal failure
   Bleeding
   Thrombosis
   Neuropathy
   Compression fracture of   column vertebra
76/24
2 (8)
7 (28)
13(52)
2 (8)
1(4)
1 (4)
1 (4)
1 (4)
1 (4)
1 (4)
15 (60)
1 (4)
4 (16)
4 (16)
5 (20)
1( 4)
1 (4)
1 (4)
2 (12)
10 (40)
History of  the past treatment (%)
   No treatment
   With treatment
13 (52)
12 (48)
Durie-Salmon staging (%)
   I
   II
   IIIA/IIIB
0
1 (4)
24(96)
International System Staging (ISS)
  I
  II
  III
4 (16)
5 (20)
16 (64)
*Median , (SE Median)
The most complication in patients with 
MM is fracture; compression of  lumbar 
vertebra 10 cases (40%) and fracture another 
site 4 cases (16%). According to Durrie 
Salmon staging system, 96% patients have 
stage III A/IIIB. However, according to the 
International staging system, 64% patients 
have stage III.
According to immunoisotype, total case 
of   IgG κ , IgA κ, IgA λ, biclonal λ light cain 
and IgG λ were 11 patients (44%), 2 patients 
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men, and 63 years for women.15 Median age, 
according to Dispezieri (2009) was 71 years. 5 
Median age of  Kariyawasan CC study (2007),16 
was 66 years. The median age in our study was 
lower than other studies. Man to woman ratio 
was 3.1: 1, this number is similar to the studies 
in other countries. The incidence of  patients 
with MM was higher in men than in women, 
this result similar to another study.5, 17
Bone pain was the main complaint of  
MM patients in this study, 60%. In a study by 
Kariyawasan CC, et al (2007),17 56% patients 
experienced bone pain ranging from mild, 
moderate, to severe. Bone involvement rather 
than symptomatic bone pain, bone lytic lesion 
and/or severe osteoporosis were the main 
features in patients with MM. 18
Other complaints were swelling, tumor 
mass, petechiae, fatigue, fracture and sort of  
breath.  Bone swelling and bone mass were 
caused by bone destruction. When a solitary 
mass appeared, this bone mass was called 
plasmacytoma. 19,20
The complication of  infection is usually 
found in MM patients.  Patients with MM 
have decreased of  immunity that resulted in 
susceptibility to infection. Disturbance in 
humoral immunity and leucopenia make 
patients with MM prone to infection. Patients 
with multiple myeloma were more susceptible to 
bacterial infections, especially from encapsulated 
microorganisms, such as pneumococcus, as well 
as a viral infection.21  The study in Japan revealed 
that patients with MM have risk of  bacterial 
infection include Streptococcus pneumoniae, 
Haemophilus infl uenzae, and Escherichia coli. 
Sulfamethoxazole – trimethoprim oral for at 
least the fi rst 2 months of  chemotherapy were 
important prophylaxis for bacterial infection.22  
Hypercalcemia was due to bone destruction 
in MM. Bone destruction mechanism and 
disability of  osteoblast to repair bone lesions in 
clinical remission phase have been understood.23 
Incidence of  hypercalcemia in patients with MM 
was 20%, however all of  the patient in this study 
have no hypercalcemia.
Most of  the patients with MM came 
to hospital in advanced stage. According to 
Durrie Salmon staging system, 96% patients 
have stage III A or IIIB. However, according to 
the international staging system, 64% patients 
have stage III. These were caused by delay 
diagnosis and referral.  Many patients came to 
a Neurologist, Nephrologist, and Orthopedist. 
Diagnosing MM in early stage is diffi cult, as 
shown in the result of  this study; we should have 
more awareness in patients with bone pain.
The study in Taiwan revealed a correlation 
between farming exposure and MM. However, 
in this study, almost all of  the population 
were private employees that have no farming 
exposure. There are many risk factors for MM. 
Although there were correlations between toxin, 
dietary source, environment pollution and 
increasing MM incidence, these fi ndings still 
need epidemiology analysis in the future.  14
All patients in this study have anemia. 
Anemia in patients with MM is anemia of  
chronic disease that caused by blunting of  
response to erythropoietin (EPO) and disorder 
of  iron metabolism.24
This study has some limitations, because 
there were no analysis of  parameters such 
as performance status, C reactive protein, 
chromosome 13 abnormalities, and plasma 
cell labeling index (PCLI).  
CONCLUSION
The characteristic data of  patient with 
MM at dr. Kariadi Hospital similar to other 
Suharti et al.
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center. Almost the patient came to the hospital 
with advanced stage, bone complication, 
infection etc. There, interest data was the age 
patients with MM were younger than another 
center. 
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